Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,592 shares, an increase of 92.7% from the June 15th total of 1,864 shares. Based on an average trading volume of 7,451 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the shares of the company are sold short.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of Invesco Biotechnology & Genome ETF stock traded up $1.56 during trading on Thursday, hitting $91.08. 1,263 shares of the company’s stock were exchanged, compared to its average volume of 6,909. The stock has a market capitalization of $285.99 million, a price-to-earnings ratio of 20.44 and a beta of 0.70. The business has a 50-day simple moving average of $85.48 and a 200-day simple moving average of $82.43. Invesco Biotechnology & Genome ETF has a 52-week low of $63.92 and a 52-week high of $94.06.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. lifted its position in shares of Invesco Biotechnology & Genome ETF by 1.8% during the 3rd quarter. Raymond James Financial Inc. now owns 8,078 shares of the company’s stock valued at $564,000 after buying an additional 141 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Invesco Biotechnology & Genome ETF by 18.1% in the 4th quarter. NewEdge Advisors LLC now owns 1,043 shares of the company’s stock worth $86,000 after acquiring an additional 160 shares in the last quarter. Comerica Bank raised its position in Invesco Biotechnology & Genome ETF by 86.2% during the fourth quarter. Comerica Bank now owns 378 shares of the company’s stock worth $31,000 after acquiring an additional 175 shares during the period. PNC Financial Services Group Inc. raised its position in Invesco Biotechnology & Genome ETF by 74.5% during the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after acquiring an additional 245 shares during the period. Finally, Newman Dignan & Sheerar Inc. lifted its holdings in Invesco Biotechnology & Genome ETF by 3.0% during the fourth quarter. Newman Dignan & Sheerar Inc. now owns 10,070 shares of the company’s stock valued at $827,000 after purchasing an additional 298 shares in the last quarter.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.